Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China.
J Cell Mol Med. 2024 Jun;28(11):e18362. doi: 10.1111/jcmm.18362.
Chimeric antigen receptor- (CAR-)modified T cells have been successfully used to treat blood cancer. With the improved research on anti-tumour adoptive cell therapy, researchers have focused on immune cells other than T lymphocytes. Natural killer (NK) cells have received widespread attention as barriers to natural immunity. Compared to T lymphocyte-related adoptive cell therapy, the use of NK cells to treat tumours does not cause graft-versus-host disease, significantly improving immunity. Moreover, NK cells have more sources than T cells, and the related modified cells are less expensive. NK cells function through several pathways in anti-tumour mechanisms. Currently, many anti-tumour clinical trials have used NK cell-related adoptive cell therapies. In this review, we have summarized the recent progress in NK cell-related adoptive cellular immunotherapy for tumour treatment and propose the current challenges faced by CAR-NK cell therapy.
嵌合抗原受体- (CAR-) 修饰的 T 细胞已成功用于治疗血液癌症。随着抗肿瘤过继细胞疗法研究的不断深入，研究人员的关注点已不仅仅局限于 T 淋巴细胞，而是转向了自然杀伤 (NK) 细胞等免疫细胞。自然杀伤细胞作为天然免疫的屏障而受到广泛关注。与 T 淋巴细胞相关的过继细胞疗法相比，使用 NK 细胞治疗肿瘤不会引起移植物抗宿主病，从而显著提高免疫力。此外，NK 细胞的来源比 T 细胞更多，相关修饰细胞的成本也更低。NK 细胞通过几种途径在抗肿瘤机制中发挥作用。目前，许多抗肿瘤临床试验都采用了 NK 细胞相关的过继细胞疗法。在本文中，我们总结了 NK 细胞相关过继细胞免疫疗法治疗肿瘤的最新进展，并提出了 CAR-NK 细胞治疗目前面临的挑战。
